Background Used in combination with antiretroviral therapy, subcutaneous recombinant
interleukin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The …

The CD4 lymphocyte count and risk of clinical progression : Current Opinion in HIV and AIDS
The CD4 lymphocyte count and risk of clinical progression : Current Opinion in HIV and AIDS …

Immune‐based therapy (IBT) interventions have found a window of opportunity within some
limitations of the otherwise successful combined antiretroviral therapy (cART). Two major …

Standard-dose intravenous recombinant interleukin-2 (rIL-2) is indicated for the treatment of
some subtypes of cancer; however, severe adverse events, including venous …

Background: Intermittent interleukin-2 (IL-2) therapy leads to a sustained increase of CD4 T
cells in HIV-1-infected patients. Methods: Symptom-free HIV-1-infected patients who were …

Background: Despite effective highly active antiretroviral therapy (HAART), some patients
infected with HIV have persistently low CD4 cell counts with risk of HIV disease progression …

Abstract Interleukin (IL)–18 is an interferon (IFN)–γ-inducing factor and contributes to the
Th1 immune response. IL-18 added after infection of peripheral blood mononuclear cells …

Control of viral replication to below the level of quantification using combination antiretroviral
therapy (ART)[cART] has led to a dramatic fall in mortality and morbidity from AIDS …

Since the discovery and synthesis of a novel DNA mimic, peptide nucleic acid (PNA) in
1991, PNAs have attracted tremendous interest and have shown great promise as potential …

[12, 20]. HAART appears to increase APC numbers to an extent, but they are still below
normal levels after six months of HAART (S. Patterson personal communication). In no …